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Abstract
The metastasizing capacity of the rat pancreatic adenocarcinoma BSp73ASML (ASMLwt) is strikingly reduced by a
knockdown of CD44v4-v7 (ASMLkd). We used this model to analyze the role of the CD44 variant isoform (CD44v) in
(pre)metastatic niche formation. Intrafootpad injections of ASMLwt–, but not ASMLkd–conditioned medium (CM),
strongly promote settlement of ASMLkd cells in lymph nodes and lung. Fractionation of CM revealed a contribution
by a soluble matrix and exosomes, where the CD44v6-containing ASMLwt–soluble fraction can complement
ASMLkd-exosomes, but not vice versa. This implies that exosomes are the final actors, are CD44v-independent, but
require a soluble matrix, which depends on CD44v. Analyzing the composition revealed that only the ASMLwt-matrix
contains c-Met and urokinase-type plasminogen activator receptor. In vitro, mostly ASMLwt-exosomes promote pro-
liferation and induce gene expression in metastatic organ cells. However, in vivo corresponding changes in the (pre)
metastatic organ are only observed when both, exosomes plus the soluble matrix, are provided. Thus, neither CD44v
nor exosomes alone suffice for (pre)metastatic niche formation. Instead, CD44v suffices for assembling a soluble
matrix, which allows exosomes, independent of their origin from poorly or highly metastatic cells, to modulate (pre)
metastatic organ cells for tumor cell embedding and growth.
Neoplasia (2009) 11, 1093–1105
Introduction
Metastasis formation relies on an interaction with the primary tumor’s
surrounding [1], where a small population of cancer-initiating cells
(CICs) [2,3] may account for metastasis formation by organizing a
niche in the (pre)metastatic organ [3–5], which implies long-distance
communication of CIC.
CICs are defined by a set of markers [3,6], one of which, CD44, is
expressed in several types of leukemia and carcinoma [7].CD44 contrib-
utes to hematopoietic and leukemic stem cell settlement [8,9]. It plays
an important role in leukocyte and metastatic cell motility through
hyaluronic acid (HA) binding [10] or association with integrins, cyto-
skeletal proteins, and metalloproteinases (MMPs) [11–14]. CD44 con-
tributes to stem cell and metastatic cell mobilization by interacting with
c-Met [15–17] and protects from apoptosis by interfering with receptor-
mediated apoptosis and by activating antiapoptotic proteins [18,19].
Overexpression of CD44v6 promotes metastasis formation [20], which
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was confirmed by a selective knockdown of CD44v4-v7 (ASMLkd)
[21] in the highly metastatic BSp73ASML cell line (ASMLwt) [22].
Settlement of metastasizing tumor cells is facilitated by the establish-
ment of special niches in (pre)metastatic organs [23]. Niche preparation
involves stimulation of local fibroblasts by tumor-derived factors and
chemokines that attract tumor cells and hematopoietic progenitors
[24], lysyl oxidase being important for marrow cell recruitment [25].
Nonetheless, information on long-distance communication between a
tumor and the host organs is still limited. We suggest that tumor cells
avail special delivery systems and hypothesize that a concerted activity
between tumor-derived factors and exosomes is required [26].
Exosomes, small, multivesicular body (MVB)–derived vesicles, are abun-
dantly released by tumor cells on fusionwith the plasmamembrane [27,28].
Exosomes harbor, besides a common set of membrane and cytosolic mole-
cules, cell type–specific proteins that maintain functional activity [28–30].
Exosomes also containmessengerRNA (mRNA) andmicroRNA (miRNA)
that are transferred to target cells, where they can be translated or mediate
RNA silencing [31]. Exosomes function as a potent tool for intercellular
communication and gene delivery also in metastasis [28,29].
To prove our hypothesis that tumor-derived factors suffice to pro-
mote metastasis formation, we made use of ASMLwt and ASMLkd cells.
ASMLwt cells metastasize through the lymphatics to the lung but do not
grow locally [22]. ASMLkd cells poorly metastasize, which might be
a sequel of a defect in a CD44 variant isoform (CD44v)–assembled
soluble matrix, which promotes adhesion and apoptosis resistance
[21]. Because the ASML tumor does not grow locally, likely because
of a defect in angiogenesis induction [22], this model should allow to
study the role CD44v takes in creating a metastasis-supporting environ-
ment and to define which tumor-derived components suffice for the
cross talk between a tumor and the (pre)metastatic organ.
Materials and Methods
Rats and Tumors
Specific pathogen-free BDX rats were fed sterilized food and water
ad libitum. ASMLwt and ASMLkd clones of a BDX pancreatic adeno-
carcinoma [21,22], a BDX lung fibroblast (LuFb), a rat lymph node
stroma (LnStr) [32], and a rat aortic endothelial cell line (RAEC) were
maintained in RPMI-1640/10% fetal calf serum. Confluent cultures
were trypsinized and split.
Antibodies
Primary antibodies are listed in Table W1. Streptavidin-HRP and
dye-labeled secondary antibodies were obtained from Dianova, Ham-
burg, Germany.
Flow Cytometry
Cells (2-5 × 105) were stained according to routine procedures.
For intracellular staining, cells were fixed and permeabilized. Samples
were processed in a FACSCalibur using the Cell Quest program for
analysis (BD, Heidelberg, Germany).
Reverse Transcription–Polymerase Chain Reaction
Total RNAwas extracted using TRIzol reagent (Invitrogen, Karlsruhe,
Germany). Reverse transcription–polymerase chain reaction followed
routine procedures. Primers are listed in Table W2.
Cell and Tissue Preparation
Lymph nodes (LN), femur, and lung were aseptically removed.
Bone marrow (BM) was flushed out of the femur, and the lung tissue
was cut into small pieces. Tissues were meshed through fine gauze.
Fractionation of Conditioned Medium
Tumor cells were cultured for 24 hours in serum-free medium. The
supernatant was collected and centrifuged (10minutes at 1000g, 1500g,
or 2000g). For vesicle depletion, this conditioned medium (CM) was
centrifuged for 20 minutes at 10,000g and 90 minutes at 26,000g.
The vesicle-depleted CM is termed “soluble fraction.” The soluble
fraction contains a strongly adhesive subfraction [21], which was recov-
ered as the plastic adherent fraction after culturing tumor cells for
24 hours in serum-free medium and removing the cells by EDTA treat-
ment. Exosomes were pelleted by centrifugation (64,000g for 90 min-
utes) and resuspended in PBS.
SDS-PAGE and Western Blot
Samples were resolved on 10% SDS-PAGE. Proteins were transferred
to nitrocellulosemembranes (30V for 16 hours at 4°C), andmembranes
were blocked, blottedwith streptavidin or primary andHRP-conjugated
secondary antibodies (1 hour at room temperature) and developed with
the ECL Kit (Amersham Life Sciences, Braunschweig, Germany). For
matrix-assisted laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI-TOF) analysis, gels were fixed for 16 hours in 150 ml of
ethanol, sensitized for 45 minutes in 0.3 M K-tetrathionate, 0.5 M
K-acetate, and 30% ethanol. Gels were washed (H2O; six times for
10minutes each) and incubated for 1 hour in 2% silver nitrate. Gels were
developed in 0.5 M K-carbonate, 10% Na-thiosulfatepentahydrate, and
0.01% formalin. The reaction was stopped (0.5 M Tris-HCl, 2% acetic
acid), and gels were washed (twice for 30 minutes each).
MALDI-TOF Mass Spectrometry
Gels were silver-stained. Protein digestion, sample preparation,
MALDI-TOF fingerprint analysis, postsource decay fragmentation
analysis, and database searches were performed as described [33].
Histology
Cryostat sections (5-7 μm) of snap-frozen tissue were fixed, stained
with the indicated antibodies, washed, and exposed to biotinylated sec-
ondary antibodies and alkaline phosphatase–conjugated avidin-biotin
Figure 1. The impact of tumor cell CM on metastasis. (A–C) BDX rats received five daily IFP injections of ASMLwt-CM or control medium,
at day 5 concomitantly with ASMLwt or ASMLkd cells. Thereafter, medium/CMapplication was repeated twice per week. Ratswere killed 4 to
28 days after tumor cell application. (A) The number of tumor cells (C4.4A+) was evaluated in LN and lung by flow cytometry. Mean values±
SD of three rats per group are shown. (B) Representative examples of tumor cell settlement in LN and lung (C4.4A+) are presented. (C) The
mean number ± SD of draining LNC (subtracting the number of tumor cells). (D) Representative examples of LN and lung sections stained
with the indicated antibodies are shown. Scale bar: B and D, 0.5 μm. (A and C) Significant differences between rats receiving control medium
versus CM are indicated by ★. ASMLwt-CM supports settlement and growth of a weakly metastatic tumor line in draining LNs and lung.
ASMLwt-CM also recruits leukocytes into the draining LNs and promotes leukocyte activation.
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complex solution. Sections were counterstained with hematoxylin.
For fluorescence staining of deposited matrix, cells were grown for
48 hours on cover slides. Cells were removed by prolonged EDTA
treatment, and slides were blocked and stained with the indicated
antibodies and washed and mounted in Elvanol (Sigma Diagnostic,
Munic, Germany). Digitized images were generated using a Leica
DMRBE microscope (Leica Microsystems, Wetzlar, Germany).
Proliferation Assay
Triplicates of LnStr, LuFb, RAEC (5 × 104) or LNor BMcells (LNCs
or BMCs; 2 × 105) were cultured in the presence of CM or fractions
thereof. Proliferation was determined after 48 hours by MTT staining.
Apoptosis Induction
Cells were cultured in 96-well plates in RPMI containing cisplatin
(cis-diamineplatinum(II) dichloride; Sigma, Munich, Germany) and/or
CM or fractions thereof. Survival was monitored after 48 hours by
annexin V/propidium iodide or evaluation of the percentage of respira-
tory active cells (MTT assay).
Adhesion Assay
Cells (1 × 106) were suspended in RPMI, CM or fractions thereof
and seeded on plastic or adhesive matrix-coated 24-well plates. After
30 minutes at 37°C, nonadherent cells were washed off. Adherent cells
were fixed, crystal violet–stained, and lysed. Absorbance was measured
at 595 nm. Adhesion is presented as percentage of input cells.
Migration Assay
Cells were seeded in the upper part of a Boyden chamber in 30 μl of
RPMI/0.1% BSA. The lower part, separated by an 8-μm (adherent
cells) or 5-μm (leukocytes) pore size polycarbonate membrane (Neuro-
probe, Gaithersburg, MD), contained 30 μl of RPMI/0.1% BSA, CM,
Figure 2. The impact of tumor cell–derived exosomes on metastasis. BDX rats were conditioned as above with control medium, CM, the
soluble fraction, or exosomes of (A) ASMLwt or (B) ASMLkd cells or (C) ASMLwt–soluble fraction and ASMLkd–soluble fraction and exosome
mixtures. At day 5, all rats received ASMLkd cells, IFP. Application of CM or fractions thereof was repeated twice per week. Rats were killed
7 to 14 days after tumor cell application. Themean number ± SD of tumor cells (C4.4A+) in the popliteal LN and the number of leukocytes in
the popliteal and para-aortic LN (subtracting the number of tumor cells) are shown. Significant differences between rats receiving control
medium versus CM or fractions thereof are indicated by ★. (D) Summary of the impact of CM and fractions thereof on gene expression
in draining LN leukocytes 10 days after tumor cell application. Distinct colors indicate strong and light colors weak up-regulation. The
ASMLwt–soluble fraction does not suffice for ASMLkd tumor cell recruitment into LN and lung and does not initiate activation of draining
LN leukocytes. However, the ASMLwt–soluble fraction supports exosomes in both metastasis formation and premetastatic organ leukocyte
recruitment. This is, albeit less pronounced, also the case for ASMLkd-exosomes.
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or fractions thereof. Leukocytes in the lower chamber were counted after
4 hours. Migration of adherent cells was evaluated after 16 hours by
staining the lower membrane side with crystal violet. After lysis, OD
at 595 nm was measured. Migration is presented as percentage of input
cells. In wound healing assays, semiconfluentmonolayers were scratched.
Medium was changed adding RPMI, CM, or fractions thereof. Migra-
tion was documented after 24 to 48 hours by light microscopy.
Zymography
LnStr, LuFb, and RAEC were lysed after overnight culture in the
presence of CM or fractions thereof. Lysates, CM, the soluble fraction,
or exosomes were incubated with Laemmli buffer (15 minutes at 37°C)
and separated in a 10% acrylamide/1 mg/ml gelatin gel. Gels were
washed and stained with Coomassie blue.
In Vivo Assay
Female rats (10-14 weeks old) received five daily intrafootpad
(IFP) injections (150 μg/25 μl) of control medium, CM, or fractions
thereof at day 5 concomitantly with tumor cells (1 × 106) and, thereafter,
two injections per week. Rats were killed after 4 to 28 days. The pop-
liteal, inguinal, para-aortic, and mesenteric LN, BM, and lung were
excised. Tissues were shock frozen or meshed. Animal experiments were
approved by the local government authorities.
Statistics
Significance was calculated by the Student’s t test. In vitro assays (trip-
licates) were repeated three times.
Results
ASMLwt CM Supports Metastatic Spread of ASMLkd Cells
To explore whether ASMLwt-derived soluble factors suffice to prepare
a niche that allows embedding and growth of poorly metastatic ASMLkd
cells, rats received 150 μg of ASMLwt-CM, IFP, on five consecutive
days, at day 5 concomitantly with ASMLwt or ASMLkd cells. Thereafter,
application of CM was repeated twice per week. Rats were killed, and
draining LNs and lung was excised 4 to 28 days after tumor cell appli-
cation. During this period, a significantly increased number of ASMLkd
cells were recovered in draining LNs and lung in rats receiving ASMLwt-
CM.No tumor cells were recovered in the lung of control rats (Figure 1,
A and B). In addition, a higher number of leukocytes were recovered
in ASMLkd-bearing rats that received ASMLwt-CM (Figure 1C ). In
ASMLwt-bearing rats, the number of tumor cells and of leukocytes
was hardly affected by ASMLwt-CM (Figure 1, A–C ). Strongly up-
regulated expression of CD49c, CD49d, and CD54 and distinctly up-
regulated expression of urokinase-type plasminogen activator receptor
(uPAR) and vascular endothelial growth factor receptors 1 and 2
(VEGFR1 and VEGFR2) are prominent ASMLwt-CM–induced altera-
tions in the popliteal LNs and the lung. Unexpectedly, because ASMLwt
cells hardly induce angiogenesis, LNs contain few but very strongly
CD31+ capillaries. CD31 expression is also upregulated in the lung.
The most striking feature are CD11b+ clusters in the LNs, which,
although smaller, are also seen in the lung (Figure 1D).
These data show that ASMLwt cells deliver messages that suffice for
significant alterations in premetastatic organs, which allow a poorly me-
tastatic cell line to reach, settle, and grow in LNs and the lung. We had
shown before that ASMLwt cells deliver a soluble matrix, which sup-
ports tumor cell adhesion and apoptosis resistance [21], but also that
tumor-derived exosomes can exert systemic effects such as angiogenesis
induction in tumor-free organs [34]. Because of the large array of
activities, which a tumor cell has to fulfill to reach the state of metastatic
growth, we considered it unlikely that a single tumor-derived factor
sufficed to account for premetastatic niche preparation and hence pro-
ceeded to evaluate whether the ASMLwt-derived soluble or the vesicular
fraction, particularly exosomes, support ASMLkd cells in progressing
through the metastatic cascade.
An ASMLwt–Soluble Fraction Cooperates with Exosomes to
Support Metastatic Spread
To examine which components of the ASMLwt-CM account for the
metastasis-supporting effect, a soluble fraction was separated from exo-
somes. Settlement of ASMLkd cells and leukocyte expansion/recruitment
were more efficiently facilitated by ASMLwt-exosomes than the soluble
fraction. However, neither exosomes nor the soluble fraction reached the
efficacy of CM. Because it was apparent that both the soluble fraction
and exosomes were required for accelerated metastatic spread, it was
of interest whether both fractions must be derived from a metastatic
tumor line. The evaluation of tumor cell recruitment into the draining
LNs after application of ASMLkd-CM, the ASMLkd–soluble fraction, or
the ASMLkd-exosomes revealed that ASMLkd-CM and ASMLkd-
exosomes, but not the soluble fraction, supported, albeit weakly, tumor
cell settlement. Applying a mixture of the soluble fraction and exosomes
Figure 2. (continued).
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from ASMLwt and ASMLkd cells confirmed that ASMLkd-exosomes can
cooperate with the ASMLwt–soluble fraction (Figure 2, A–C ).
An ex vivo analysis of LNC confirmed a strong effect of ASMLwt-CM
but only a weak effect of ASMLkd-CMon hematopoietic cell activation/
expansion in (pre)metastatic organs. The ASMLwt–soluble fraction
exerted no effect, and exosomes were very weakly effective; that
is, CD49b, CD49c, CD49d, stromal-derived factor 1 (SDF-1),
MMP9, MMP13, and uPAR expression only becomes stimulated by
ASMLwt-CM but not by the ASMLwt–soluble fraction and slightly by
ASMLwt-exosomes. However, upregulated gene expression was fre-
quently seen after application of the ASMLwt–soluble fraction together
with ASMLkd-exosomes (Figure 2D; examples on the relative increase in
marker expression: Figure W1).
Thus, ASMLwt-CM creates a milieu that supports metastatic settle-
ment of weakly metastasizing ASMLkd cells, but neither the ASMLwt–
soluble fraction nor the ASMLwt-exosomes alone are sufficient. Instead,
components of the ASMLwt–soluble fraction can cooperate even with
ASMLkd-exosomes but not vice versa. These findings imply that exo-
somes contain essential messages that require the ASMLwt–soluble frac-
tion for delivery. Hence, we examined differences between ASMLwt and
ASMLkd cells, the soluble fraction, and exosomes.
Impact of CD44v on Gene Expression, Protein Secretion/
Shedding, and Exosome Delivery
The plastic-deposited matrix of ASMLwt, but not ASMLkd cells,
strongly supports adhesion of both ASMLwt and ASMLkd cells [21].
This “adhesive” fraction was evaluated for the presence of matrix
proteins, growth factors, and proteases frequently deposited in the ex-
tracellular matrix. With the exception of a possibly more structured
organization of HA in the ASMLwt–adhesive fraction, no obvious dif-
ferences were observed between ASMLwt– and ASMLkd–matrix pro-
teins. However, hepatocyte growth factor (HGF), MMP13, and uPA
were reduced in the ASMLkd-matrix. Deposition of other MMPs, platelet-
derived growth factor (PDGF), SDF-1, VEGF, and thrombospondin
(TSP) was not overtly affected (Figure 3A and data not shown).
MALDI-TOFanalysis revealed a strong reduction of c-Met and com-
plement component 3 (C3) in the ASMLkd–soluble fraction and of
annexin II, annexin V, heat shock protein 1 (HSP-1), phosphoglyc-
erate kinase 1 (PGK-1), and monooxygenase activating protein in
ASMLkd-exosomes.
Western blot confirmed that besides CD44v6, c-Met, uPAR,C3,HA
synthase 3 (HAS3), and CD104 were selectively missing in the
ASMLkd–soluble fraction. C-Met, uPAR, andHAS3 expressionwas also
reduced in ASMLkd cells. Instead, C3 and CD104 were missing in the
ASMLkd–soluble fraction, but expression was not reduced in ASMLkd
cells (Figure 3B).
Exosomes are enriched in tetraspanins, tetraspanin-associated mole-
cules, glycosylphosphatidylinositol-anchored, and other raft-associated
molecules [27,29,30]. The recovery of the tetraspanins D6.1A, CD151,
CD9 and of the D6.1A-associated molecules F2 alpha receptor reg-
ulatory protein, CD13, intersectin 2 (INS-2), epithelial cell adhesion
molecule (EpCAM), and EpCAM-associated claudin-7 [27,35], as
well as of CD11a, CD49c, CD49f, and CD104 was not or only slightly
impaired in ASMLkd cells and exosomes. Even the integrin ligands
laminin 5 and fibronectin (FN) were partly recovered in exosomes.
However, HGF was absent, and recovery of annexin V, HSP-1, PGK-1,
and TSP was strongly reduced in ASMLkd-exosomes. The expression of
these proteins in ASMLkd cells was unimpaired (Figure 3C and data
not shown). Zymography revealed a reduction of MMP9 in ASMLkd-
exosomes (Figure 3D).
Taken together (Table W3), ASMLwt cells exhibit several features of
pancreatic CICs that are mostly preserved in weakly metastatic ASMLkd
cells. ASMLwt and ASMLkd cells express the CIC markers EpCAM,
α6β4, CD24, CD133, and CD166 (Figure W2). The recovery of tetra-
spanins and tetraspanin-associated molecules remained unaltered in
ASMLkd-exosomes. These findings might explain the metastasis-
supporting activity of ASMLkd-exosomes. The deficit in HGF could
account for the low efficacy of ASMLkd-exosomes. Supporting our
hypothesis that exosomes are the driving force, but essentially require
the soluble fraction, are the deficits of CD44v6, c-Met, uPAR, HAS3,
and C3 in the ASMLkd–soluble fraction, c-Met, uPAR, and HAS3 even
being reduced in ASMLkd cells.
Impact of CM on Potential Target Cells
To support our hypothesis for distinct tasks of the soluble fraction
and exosomes and their cooperativity in (pre)metastatic niche prepara-
tion, we evaluated the impact of the ASMLwt and ASMLkd soluble frac-
tion and exosomes on adhesion, migration, apoptosis resistance, and
proliferation of potential target cells, namely, LnStr, LuFb, RAEC,
LNC, and BMC, in vitro. In advance, we explored whether the soluble
fraction and the exosomes exert a similar impact on adhesion molecule,
protease, chemokine/cytokine, and receptor expression on LnStr, LuFb,
RAEC, LNC, and BMC in vivo.
As expected, the soluble fraction and exosomes influenced gene
expression when cocultured with potential target cells. However, dis-
tinct to the ex vivo analysis, the coculture system revealed that some
of the ASMLwt-CM–mediated effects are also observed with ASMLkd-
CM, although less pronounced. Furthermore, both the soluble fraction
and exosomes can modulate target cell gene expression in vitro. The
soluble fraction can influence adhesion molecule expression. Exosomes
primarily influence growth factor receptor expression. Exosomes are
also involved in the down-regulation of gene expression, mostly of
growth factors. As anticipated, not all potential target cells are equally
well responsive, and upregulated gene expression differs between dis-
tinct target cells. Some CM-mediated effects were seen with neither
the soluble fraction nor the exosomes, which indicates that, even allowing
Figure 3. Components of the deposited matrix, the soluble fraction, and exosomes. (A) ASMLwt and ASMLkd cells were seeded on cover
slides. After 48 hours, cellswere removed and thematrix was stainedwith the indicated antibodies and TxR-labeled secondary antibody. Bar,
1.5μm.There is evidence that theASMLwt-adhesivematrix can serveas a store for proteases andgrowth factors. (B andC) LysatesofASMLwt
and ASMLkd cells, the soluble fraction, and exosomeswere tested byWestern blot for the presence of the indicated proteins with emphasis
on (B) the soluble fraction and (C) exosomes. ASMLkd cells are characterized by a strong to distinct reduction in c-MET, HAS3, uPAR, and C3.
These proteins and, in addition, CD104 are absent in the ASMLkd–soluble fraction. Recovery of tetraspanin-associated exosomal proteins is
mostly unaltered; recovery of someexosomal proteins, not associatedwith tetraspanins, such asHGF, annexin V, andHSP-1,was reduced in
ASMLkd-exosomes. (D) Zymography revealed reduced recovery of MMP9 in ASMLkd-exosomes.
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for direct contact (coculture), target cell activation may require ele-
ments from both the soluble fraction and exosomes (Figure 4; detailed
information: Figure W3).
These findings confirmed that both the soluble matrix and the
exosomes exert an impact on premetastatic organs and that the soluble
matrix and the exosomes display distinct activities. In addition, it is
important to note that in vitro exosomes influenced the expression of
a large array of genes, which has not been seen in vivo. We interpret the
finding in the sense that, in vivo, the soluble matrix is required for the
delivery of exosomal messages.
Taking that the CM exerted similar effects in vivo and in vitro and
assuming that the less-pronounced effects of separated exosomes in vivo
compared with in vitro are related to inefficient targeting, the in vitro
coculture system provided a solid basis to search for distinct and joint
soluble matrix– and exosome-mediated effects on functional activities
of potential target cells.
LnStr, LuFb, and RAEC, but not LNC and BMC, adhered with
high efficacy to the ASMLwt–adhesive fraction (Figure 5A). Thus, the
ASMLwt–adhesive fraction may particularly attach to tissue stroma
and endothelial cells, which could allow delivery of messages and/or
exosomes stored within this matrix.
ASMLwt-CMand, less efficiently, ASMLkd-CMpromote LnStr, LuFb,
RAEC, and LNC but hardly BMC migration. Migration-promoting
activity is restricted to the soluble fraction, whereas exosomes show no
effect (Figure 5B).
ASMLwt cells are highly apoptosis-resistant, and apoptosis resistance
is reduced in ASMLkd cells [21]. Therefore, we tested for a protective
feature of CM on stroma cells. Indeed, ASMLwt-CM and the soluble
Figure 4. The impact of ASMLwt-CM on gene expression in target cells. LNC, LnStr, LuFb, and RAECwere cultured for 48 hours in the pres-
ence of ASMLwt- and ASMLkd-CM or fractions derived thereof. Distinct colors indicate strong and light colors weak up-regulation; stripes
indicate downregulated gene expression. In linewith the ex vivo analysis, ASMLwt-CM exerted strong effects on gene expression in potential
target cells in the (pre)metastatic organs. Distinct to the ex vivo analysis, exosomes exerted some effects in vitro, particularly on cytokine
receptor and protease expression.
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fraction promote apoptosis resistance of LnStr, LuFb, RAEC, LNC, and
BMC. However, a significant increase in cisplatin resistance is only ob-
served in LuFb. Exosomes do not protect from apoptosis (Figure 6, A
and B; data not shown).
C-Met expression is reduced in ASMLkd cells and is absent in the
ASMLkd–soluble fraction. In addition, ASMLkd-exosomes do not
contain HGF, which could affect cell cycle progression. Indeed, LnStr,
LuFb, RAEC, LNC, and BMC proliferate in response to ASMLwt-CM,
but not ASMLkd-CM, and do not proliferate or weakly proliferate
in response to the ASMLkd–soluble fraction. In LnStr, LuFb, RAEC,
and LNC, ASMLwt-exosomes but not ASMLkd-exosomes induce the
strongest response. Notably, culturing cells with a mixture of the
ASMLwt–soluble fraction and ASMLkd-exosomes significantly
strengthened proliferative activity (Figure 6C). This finding indicated
that weak proliferation induction by ASMLkd-exosomes cannot exclu-
sively rely on the deficit in HGF. Indeed, proliferation of LnStr and
LNC was strongly promoted by HGF, independent of whether the
cultures contained ASMLwt- or ASMLkd-exosomes. Instead, in LuFb,
RAEC, and BMC, slightly increased proliferative activity was seen only
on coculture with ASMLkd-exosomes plus HGF (Figure 6D). Thus,
besides HGF, additional factors will contribute to the proliferation-
supporting activity of ASMLwt-exosomes.
The in vitro analysis confirmed the superior strength of CM
compared with the soluble fraction and exosomes and provided
evidence for selective contributions of the soluble fraction versus
exosomes, which strengthens the in vivo observation that preparation
of a (pre)metastatic niche depends on cooperative activity of a
CD44v-dependent organization of a tumor-derived soluble fraction
and exosomes.
Discussion
Metastasis formation can become promoted by a (pre)metastatic niche
[1,5,23]. We hypothesized that a single or few soluble factors may not
suffice to fulfill the complex demands of the required long-distance cross
talk between a tumor and selected (pre)metastatic organs. Instead, exo-
somes, which transfer proteins, mRNA, and miRNA to selective targets
Figure 5. The impact ofCMonadhesion andmigration. (A) LnStr, LuFb, RAEC, LNCandBMCwereseeded in triplicateson flat-bottom96-well
plates coatedwithmedium or the ASMLwt- and ASMLkd-adhesivematrix. After 30minutes at 37°C, plates were washed, adherent cells were
stained with crystal violet and lysed, and OD595 nmwas evaluated. The percentage of adherent cells is shown. (B) Cells (as in A) were seeded
in the upper part of a Boyden chamber. The lower part contained RPMI/0.1% BSA or the indicated fractions. LnStr, LuFb, and RAEC were
incubated for 16 hours, whereas LNC and BMCwere incubated for 4 hours. LNC and BMC in the lower chamber were counted. LnStr, LuFb,
and RAEC at the lower membrane side were crystal violet–stained and lysed, and OD595 nm was evaluated. Significant differences in
comparison to control medium are indicated by ★; significant differences between ASMLwt- versus ASMLkd-CM and fractions thereof are
indicatedby*. LnStr, LuFb, andRAECpreferentially adhere to theASMLwt–adhesive fraction. These cells and, in addition, LNCmigrate toward
ASMLwt-CM and the ASMLwt–soluble fraction.
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[27–30], could be suitable candidates. We recently reported that the
ASMLkd distinct to the ASMLwt matrix does not promote tumor cell
adhesion and apoptosis resistance in vitro. In vivo, ASMLkd cells have
lost the highmetastatic capacity of ASMLwt cells [21]. Thus, a compari-
son of ASMLwt- versus ASMLkd-derived factors seemed suited to control
our hypothesis. Indeed, ASMLwt-CM supports ASMLkd metastases.
Exosomes play an essential role, however, only when assisted by the
ASMLwt–soluble fraction.
Consequences of a CD44vkd on CM
The ASMLwt–soluble fraction includes an adhesive subfraction,
which containsmatrix proteins also found in the correspondingASMLkd
fraction, which is not adhesive [21]. These striking functional differ-
ences may be due to the strongly reduced recovery of HAS3 in the
ASMLkd–soluble fraction [36] andmight be supported by hyaluronidase
activity [37], key functions of HAvarying considerably with length [36].
The altered assembly of the ASMLkd-“nonadhesive” matrix also may
account for the reduced recovery of MMP13, uPA, and HGF, where
the reduction of the latter two corresponds with the absence of c-Met
and uPAR in the soluble fraction and of HGF in ASMLkd-exosomes.
CD44v6 has been recovered in the ASMLwt–soluble fraction, where
differences between ASMLwt and ASMLkd are most pronounced. The
absence of c-Met in the ASMLkd–soluble fraction likely is of major
importance for reduced metastatic capacity. Activation of c-Met pro-
motes cell survival, supports the epithelial-mesenchymal transition, cell
adhesion, andmigration, and contributes to angiogenesis [16]. CD44v6
can initiate c-Met activation through HGF binding [17]. Thus, in the
absence of CD44v6, c-Met stimulation can become hampered; the
consequence of which is reduced transcription of c-Met and c-Met–
regulated genes. UPAR, one of the c-Met–regulated genes [16,38], is
Figure 6. The impact of CM on apoptosis resistance and proliferation. Cells as in Figure 5 were cultured for 48 hours with CM or fractions
thereof. (A) Themean percentage±SD (triplicates) of apoptotic cells (Annexin V–APC/propidium iodide [PI] staining) is shown. (B) LuFbwere
cultured in the presence of the indicated ASMLwt and ASMLkd fractions and titrated amounts of cisplatin. The relative percentage (mean ±
SDof triplicates) of respiratory active LuFb in comparison to cultures without cisplatin (100%) is shown. (C) The relative increase (mean± SD
of triplicates) in 3H-thymidine incorporation compared with cells cultured in the presence of RPMI/1% BSA is presented. A 1.3-fold increase
was considered significant (dashed line). Significant differences in comparison to control medium are indicated by★; significant differences
between ASMLwt- versus ASMLkd-CM and fractions thereof are indicated by *. (D) The relative increase (mean ± SD of triplicates) in
3H-thymidine incorporation in the presence of 5 ng/ml HGF is shown. A significant increase in proliferation by HGF is indicated by ★.
ASMLwt-CM and the ASMLwt–soluble fraction exert a weak apoptosis protective effect on all tested cell lines. Cisplatin resistance was only
supported by the ASMLwt–soluble fraction. Instead, ASMLwt-exosomes support LnStr, LuFb, RAEC, and LNC proliferation.
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also strongly downregulated in ASMLkd cells and is absent in the solu-
ble fraction. The absence of CD44v6 can contribute to uPAR down-
regulation, HA binding of CD44 being described to regulate uPAR
transcription [39]. UPAR is involved in uPA binding/plasminogen
activation and associates with several integrins, epidermal growth factor
receptor (EGFR), PDGFR, caveolin, and vitronectin (VN), thereby initi-
ating signal transduction through focal adhesion kinase, Src, Akt, extra-
cellular receptor-activated kinase, and ras [40]. Thus, uPAR could
contribute to (pre)metastatic niche preparation by harboring uPA, which
is hardly detectable in the ASMLkd-adhesive matrix, and/or by binding
to integrins or EGFR and initiating signal transduction. In ASMLwt cells,
CD44v6, c-Met, and uPAR coimmunoprecipitate when cultured in
the presence of a chemical cross linker and CD44 cross linking by HA
induces c-Met activation (T. Jung, unpublished observations). These
observations are in line with the outlined hypothesis and support a cen-
tral role of CD44v6 in generating a tumor environment that can have
a strong impact on premetastatic niche preparation.
C3, although recovered in exosomes, is absent in theASMLkd–soluble
fraction. C3a could become important in (pre)metastatic niche prepa-
ration as a most potent anaphylatoxin. C3b may recruit exosomes to
monocytes through binding to the CD11b receptor [41]. Notably, as
also reported for (pre)metastatic niche formation in mammary cancer
[25], very strong clusters of CD11b+ cells were seen in draining LNs
and the lung, which has been suggested to be initiated by tumor-derived
chemoattractants S100A8 and S100A9 [42].
These differences in the ASMLwt–soluble fraction versus the
ASMLkd–soluble fraction are in line with preferentially the ASMLwt–
soluble fraction supporting migration and apoptosis resistance of tar-
get cells on the way to and within the premetastatic organ. Work is in
progress to define themolecular pathways whereby CD44v6 assembles a
soluble matrix that supports premetastatic niche formation.
Exosomes can support metastasis formation [43,44]. ASMLwt-
exosomes, too, distinct to the soluble fraction, exert some effect on pre-
metastatic niche preparation. These effects, albeit weakened, can also be
seen with ASMLkd-exosomes. Therefore, we suggest that the CD44vkd
did not affect exosomal components essential for niche preparation
but affected components that strengthened the efficacy of exosomes.
In our first trial to separate “essential” from “supporting” exosomal
components, we differentiated between exosomes derived from distinct
membrane domains.
Recovery of tetraspanins (CD9, CD151, D6.1A) and D6.1A-
associated proteins (F2 alpha receptor regulatory protein, CD13,
INS-2, CD49c, CD49fCD104, EpCAM, claudin-7) [27] is unim-
paired in ASMLkd-exosomes. In view of the unaltered tetraspanin
web in ASMLkd-exosomes, it becomes likely that 1) invagination
of caveolae or clathrin-coated pits [25], but not of tetraspanin micro-
domains, is affected by a CD44vkd, the reasons of which remain to be
defined, and 2) TEM-derived exosomes are essential in (pre)metastatic
niche preparation. Tetraspanins are known to be involved in fusion
processes [27,45] and, thus, could well contribute to the target cell
Figure 6. (continued).
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delivery of exosomes. Unaltered recovery of integrins, including CD11b
and integrin ligands (FN and laminin 5) in ASMLkd-exosomes, might
additionally contribute to their metastasis-supporting activity together
with the ASMLwt–soluble fraction.
However, the CD44vkd affects the recovery of some non–TEM-
associated, likely “supporting” exosomal proteins, whose expression is
unaltered in ASMLkd cells, which points toward alterations in MVB
recruitment: Annexin V binds phosphatidylserine and thereby becomes
important in apoptotic signaling [46]. Annexin II is a high-affinity
receptor for plasmin and tenascin [47] and can contribute to the
integration of tumor-derived exosomes in the soluble tumor matrix.
HSPs, including HSP-1, are suggested to activate signaling cascades
through binding Toll-like and other receptors [48]. TSP, involved in
tumor dormancy by angiogenesis inhibition, also induces a desmoplastic
response [49,50]. Monooxygenase activating protein contributes to
detoxification of xenobiotics [51]. PGK-1, upregulated in response to
oxidative stress, is associated with poor prognosis [52]. Most striking
is the absence of HGF in ASMLkd-exosomes, which could well contrib-
ute to the lower efficacy of ASMLkd-exosomes supported by the
ASMLwt–soluble fraction in premetastatic niche preparation. Although
ASMLwt-exosomes contain HGF, proliferation of LnStr and LNC was
further strengthened by the addition of HGF. This does not exclude an
advantage in premetastatic organ cell stimulation by ASMLwt-exosome–
provided HGF. Furthermore, HGF exerted a stronger effect on LnStr
and LNC proliferation and also supported LuFb, RAEC, and BMC
proliferation in cocultures with ASMLkd-exosomes.
In line with the high recovery of HGF in ASMLwt-exosomes, growth
factor/receptor expression becomes upregulated in potential targets
and proliferation is strongly promoted. Whether this is partly due to
exosomal mRNA translation and exosomal miRNA silencing [31] re-
mains to be explored. The former may account for VEGFR expression
in non–endothelial cells, the latter for VEGF, von Willebrand factor,
and TSP down-regulation. Both phenomena were only seen after co-
culture with exosomes. The down-regulation of VEGF could explain
the very poorly vascularized ASML tumors [22]. Down-regulation of
TSP in exosomal target cells could be a compensatory mechanism,
and indeed, there has been a striking increase in the vascularization
of (pre)metastatic organs after ASMLwt-CM treatment. A differential
analysis of ASMLwt and ASMLkd exosomal mRNA and miRNA and
selective knockdowns of the most interesting genes in ASMLwt cells will
allow us to answer these questions. Finally, differences in the responsive-
ness of potential target cells likely are due to the differences in the ac-
tivation state of genes in the different cells and/or the selective nature of
exosome-target interactions [26,28].
Cooperative Activity of the Soluble Fraction and Exosomes
Metastasis formation of ASMLkd cells was strongly promoted by
ASMLwt-CM and quite efficiently by a mixture of the ASMLwt–soluble
fraction with ASMLkd-exosomes. Ex vivo analysis of draining LNC
confirmed that no significant changes in marker profiles were induced
by the ASMLwt–soluble fraction. Exclusively, the ASMLwt, but not the
ASMLkd-exosomes, promoted few changes: most prominently is a
higher percentage of CD11b+ cells. Instead, ASMLwt-CM had a similar
impact on protein expression in vivo and in vitro. These findings imply
that exosomes contain essential messages for (pre)metastatic niche prep-
aration, which are not delivered or do not reach the premetastatic
organ, except if assisted by the soluble fraction or by the adhesive
matrix. The fact that the ASMLwt–soluble fraction, which—distinct
to the ASMLkd–soluble fraction—contains CD44v, c-Met, uPAR
and C3, promotes adhesion, migration, and apoptosis resistance in vitro
and makes an active contribution of the soluble matrix to target activa-
tion in the premetastatic organ most likely. The adhesive subfraction
may also be a store for exosomes as supported by the recovery of
HGF. Reaching the target can become facilitated by proteases, which
are more abundant in the ASMLwt–soluble fraction. Finally, the adhe-
sive fraction, although not forming a peritumoral matrix, may attach to
the lymphatic endothelium, thus serving as a slide bar for exosomes.
It should also be noted that the ASMLwt-CM/the soluble matrix plus
exosome-induced changes in the premetastatic organs correspond well
with the features of a premetastatic niche described so far in several
murine models. We are currently evaluating the impact of the soluble
matrix, in particular that of CD44v, on exosome transport and activity.
We will proceed to clarify the mode of interaction of exosomes with
target cells on the way to and within premetastatic organs.
In summary, taking advantage of the loss of metastasis formation by
a selective CD44v knockdown in a highly metastatic rat pancreatic
adenocarcinoma, which does not form a primary tumor, we demon-
strate that CD44v is required for the assembly of a soluble matrix that,
in cooperation with exosomes, promotes leukocyte, stroma, and endo-
thelial cell activation in the (pre)metastatic organ. Exosomes are the
main actors in (pre)metastatic niche preparation. However, exosomes
essentially depend on the support of the soluble tumor-derived fraction,
which may serve as an exosome carrier and/or a reservoir for growth
factors, chemokines, and proteases.
This is the first demonstration that premetastatic niche preparation
requires two components, a soluble matrix that supports exosomes in
modulating the target cells in the premetastatic organ. It is also the first
report to define the activity of CD44v as a cancer initiating cell marker
in tumor progression. Although exemplified in an animal model, these
findings are demanding to become controlled for their relevance in
human cancer progression.
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Table W1. List of Antibodies.
Antibody Supplier
α6β4 Clone B5.5 [1]
Actin BD, Heidelberg, G.
Annexin V Santa Cruz, Heidelberg, G.
β-Catenin BD, Heidelberg, G.
bFGF Oncogene, Boston, MA
C3 MP Biomed., Eschwege, G.
C4.4A Clone C4.4 [1]
Caveolin BD, Heidelberg, G.
CD44s Clone Ox50 (EAACC)
CD44v6 Clone A2.6 [1]
CD104 BD, Heidelberg, G.
CD106 Biozol, Eching, G.
CD11a BD, Heidelberg, G.
CD11b Clone Ox42 (EAACC)
CD11c Clone Ox41 (EAACC)
CD13 [2]
CD133 Abcam, Cambridge, UK
CD151 [3]
CD18 BD, Heidelberg, G.
CD24 Santa Cruz, Heidelberg, G.
CD29 BD, Heidelberg, G.
CD31 BD, Heidelberg, G.
CD49a BD, Heidelberg, G.
CD49b BD, Heidelberg, G.
CD49c BD, Heidelberg, G.
CD49d BD, Heidelberg, G.
CD49e BD, Heidelberg, G.
CD49f Abcam, Cambridge, UK
CD53 BD, Heidelberg, G.
CD54 Biozol, Eching, G.
CD61 Biozol, Eching, G.
CD81 Santa Cruz, Heidelberg, G.
CD9 BD, Heidelberg, G.
Claudin-7 [4]
c-Met New England Biolabs, Frankfurt, G.
Collagen I Rockland, Gilbertsville, PA
Collagen II LabVision, Fremont, CA
Collagen III ARB, Golden, CO
Collagen IV Rockland, Gilbertsville, PA
D6.1A Clone D6.1 [1]
EpCAM Clone D5.7 [1]
EWI-F [5]
EGFR Santa Cruz, Heidelberg, G.
FN BD, Heidelberg, G.
Galectin Santa Cruz, Heidelberg, G.
HAS3 Abcam, Cambridge, UK
HSP-1 Santa Cruz, Heidelberg, G.
Hyaluronan Rockland, Gilbertsville, PA
INS-2 Santa Cruz, Heidelberg, G.
Laminin 1 Rockland, Gilbertsville, PA
Laminin 5 BD, Heidelberg, G.
MMP13 Dianova, Hamburg, G.
MMP2 Dianova, Hamburg, G.
MMP9 Dianova, Hamburg, G.
Osteopontin Santa Cruz, Heidelberg, G.
PDGF BD, Heidelberg, G.
PDGFR BD, Heidelberg, G.
PGK-1 Santa Cruz, Heidelberg, G.
S100A4 Abcam, Cambridge, UK
SDF-1 Abcam, Cambridge, UK
Tenascin LabVision, Fremont, CA
TGFβ Santa Cruz, Heidelberg, G.
Thrombospondin Santa Cruz, Heidelberg, G.
TNFα BD, Heidelberg, G.
uPA Calbiochem, Darmstadt, G.
uPAR Calbiochem, Darmstadt, G.
VEGF Biotrend, Köln, G.
VEGFR1 Biotrend, Köln, G.
VEGFR2 Biotrend, Köln, G.
VN Biotrend, Köln, G.
vWF Abcam, Cambridge, UK
CD44s indicates CD44 standard isoform; EAACC, European Association of Animal Cell Cultures,
Porton Down, UK; G., Germany.
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Amplification was performed for 30 cycles starting with 1 μg of complementary DNA. Annealing
temperatures have been as follows: CD133, 57°C; CD24 and CD166, 60°C; and GAPDH, 55°C.
Polymerase chain reaction products were separated by electrophoresis in a 1.5% agarose gel.
Figure W1. The impact of ASMLwt-CM on gene expression in target cells. BDX rats received ASMLwt- or ASMLkd-CM or fractions thereof
and thereafter ASMLkd cells as described in Figure 1. LN and lung leukocytes were isolated. Expression of (A) integrins, (B) chemokines,
chemokine receptors, and (C) matrix degrading enzymes was evaluated by flow cytometry. The percentage of stained cells (mean ± SD
of three experiments) is shown. Significant differences between control medium versus CM and fractions thereof are indicated by ★;
significant differences between ASMLwt- versus ASMLkd-CM and fractions thereof are indicated by *.
Table W3. ASMLwt Versus ASMLkd Cells: Protein Expression and Recovery in the Soluble Matrix
and in Exosomes.
Marker Cells Soluble Fraction Exosomes
wt/kd wt/kd wt/kd
Metastasis markers
CD44 +/+ nt/nt nt/nt
CD44v6 +++/−− +++/−− −−/−−
EpCAM +++/+++ −−/−− +++/+++
CD133 ±/± nt/nt nt/nt
CD166 ±/± nt/nt nt/nt
C4.4A +++/+++ −−/−− +++/+++
α6β4 +++/++ +/−− +++/+++
CD24 +/+ −−/−− +/+
S100A4 ++/++ −−/−− ++/++
Matrix proteins
Coll I ++/++ ++/++ nt/nt
Coll II ++/++ ++/++ nt/nt
Coll III +/+ +/+ nt/nt
Coll IV ++/++ ++/++ nt/nt
FN ++/++ ++/++ ±/±
Galectin 3 +++/+++ +++/+++ nt/nt
HA +++/+++ +++/+++ nt/nt
LN1 +++/+++ +++/+++ nt/nt
LN5 +++/+++ ++/++ +/+
Tenascin ++/++ ++/++ nt/nt
VN ++/++ ++/++ nt/nt
Adhesion molecules
CD11a +/+ ±/± +/+
CD11b +/+ −−/−− +/+
CD11c +/+ −−/−− +/+
CD18 +/+ ±/± +/+
CD29 +++/+++ +/+ +++/+++
CD49b +/+ −−/−− +/+
CD49c +/± −−/−− ++/++
CD49d ±/± −−/−− ±/±
CD49e +/+ ±/± +/+
CD49f ++/++ −−/−− ++/++
CD61 ±/± −−/−− nt/nt
CD104 +++/+++ +/−− +++/+++
Enzymes and receptors
uPA ++/++ nt/nt nt/nt
uPAR +++/± ++/−− +++/++
MMP2 ++/++ +/+ ++/++
MMP9 +/+ +/+ +/±
MMP13 +/+ −−/−− +/+
CD13 ++/++ ++/+ ++/++
HAS3 ++/+ ++/−− −−/−−
PGK-1 +++/+++ +/+ ++/±
Tetraspanins
CD9 +++/+++ ++/++ +++/+++
CD81 +++/+++ −−/−− +++/+++
CD151 ++/++ ++/++ +++/+++
D6.1A +++/+++ −−/−− +++/+++
Cytokines and receptors
HGF ++/++ −−/−− ++/−−
PDGF +/+ nt/nt nt/nt
SDF-1 +/+ +/+ nt/nt
VEGF +/+ +/+ nt/nt
OPN +/+ −−/−− −−/−−
TSP ++/++ ±/± ++/+
c-Met ++/± ++/−− −−/−−
VEGFR1 +/+ nt/nt nt/nt
VEGFR2 +/+ nt/nt nt/nt
Others
C3 ++/++ ++/−− ++/++
Annexin II ++/++ −−/−− ++/−−
Annexin V ++/++ −−/−− ++/+
HSP-1 +++/+++ −−/−− +++/±
Caveolin +++/+++ −−/−− +++/+++
EWI-F ++/++ ±/± ++/++
INS-2 ++/++ +/+ ++/++
Claudin-7 +++/+++ −−/−− +++/+++
Coll indicates collagen; kd, knock down; wt, wild type; −−, negative; ±, weak; +, distinct; ++, strong;
+++, very strong; nt, not tested.
Figure W2. CICmarker expression in ASMLwt and ASMLkd cells. Ex-
pressionof theCICmarkersCD24, CD133, andCD166 inASMLwt and
ASMLkd cells was evaluated by reverse transcription–polymerase
chain reaction. These markers are expressed by both ASMLwt and
ASMLkd cells.
Figure W3. Modulated gene expression by ASMLwt–conditioned medium. (A, B, D, E, and F) LnStr, LuFb, and RAEC were cultured for
48 hours in the presence of ASMLwt- and ASMLkd-CM. (C) LNC and (G) LnStr, LuFb, and RAEC were cultured for 48 hours in the presence
of ASMLwt– and ASMLkd–soluble fraction or exosomes. Cells were harvested, and the expression of (A–C) adhesionmolecules and (D and E)
cytokines/chemokines and receptors and (F and G) matrix degrading enzymes was evaluated by flow cytometry. Mean values ± SD of three
experiments are shown. Significant differences in comparison the control medium are indicated by ★; significant differences between
ASMLwt- versus ASMLkd-CM and fractions thereof are indicated by *.
Figure W3. (continued).
